Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Fig. 1

Response to therapy and duration of response. a Waterfall plot of best response to treatment. Four patients with thymoma achieved a partial response to treatment, including three patients who received only one dose of avelumab (*). Patients with any tumor shrinkage also developed irAE. b Duration of response. Change in the size of target lesions over time during treatment and after discontinuation of therapy (until the last follow-up time point) is illustrated. Three patients (1, 3, and 6) received one dose of avelumab

Back to article page